Impact of low bone mass and antiresorptive therapy on antibiotic efficacy in a rat model of orthopedic device-related infection.
Animals
Anti-Bacterial Agents
/ therapeutic use
Bone Density Conservation Agents
/ adverse effects
Bone and Bones
/ diagnostic imaging
Disease Models, Animal
Estrogens
/ deficiency
Female
Prosthesis-Related Infections
/ complications
Rats
Rats, Wistar
Staphylococcal Infections
/ complications
Staphylococcus epidermidis
X-Ray Microtomography
Staphylococcus epidermidis
antibiotics
bisphosphonate
in vivo micro-CT
osteomyelitis
Journal
Journal of orthopaedic research : official publication of the Orthopaedic Research Society
ISSN: 1554-527X
Titre abrégé: J Orthop Res
Pays: United States
ID NLM: 8404726
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
03
09
2020
revised:
05
11
2020
accepted:
14
12
2020
pubmed:
17
12
2020
medline:
1
5
2021
entrez:
16
12
2020
Statut:
ppublish
Résumé
A significant proportion of orthopedic devices are implanted in osteoporotic patients, but it is currently unclear how estrogen deficiency and/or exposure to antiresorptive bisphosphonates (BPs) influence orthopedic device-related infection (ODRI), or response to therapy. The aim of this study is to characterize the bone changes resulting from Staphylococcus epidermidis infection in a rodent ODRI model and to determine if ovariectomy (OVX) or BP treatment influences the infection or the success of antibiotic therapy. A sterile or S. epidermidis-contaminated screw was implanted into the proximal tibia of skeletally mature female Wistar rats (n = 6-9 per group). Bone changes were monitored over 28 days using in vivo micro-computed tomography scanning. OVX was performed 12 weeks before screw implantation. The BP zoledronic acid (ZOL) was administered 4 days before screw insertion. A combination antibiotic regimen (rifampin plus cefazolin) was administered from Days 7-21. In skeletally healthy animals, S. epidermidis induced marked changes in bone, with peak osteolysis occurring at Day 9 and woven bone deposition and periosteal mineralization from Day 14 onwards. Antibiotic therapy cleared the infection in the majority of animals (2/9 infected) but did not affect bone responses. OVX did not affect the pattern of infection-induced changes in bone, nor bacterial load, but reduced antibiotic efficacy (5/9 infected). ZOL treatment did not protect from osteolysis in OVX animals, or further affect antibiotic efficacy (5/9 infected) but did significantly increase the bacterial load. This study suggests that both BPs and OVX can influence host responses to bone infections involving S. epidermidis.
Substances chimiques
Anti-Bacterial Agents
0
Bone Density Conservation Agents
0
Estrogens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
415-425Informations de copyright
© 2020 Orthopaedic Research Society. Published by Wiley Periodicals LLC.
Références
Metsemakers W, Morgenstern M, McNally MA, et al. Fracture-related infection: a consensus on definition from an international expert group. Injury. 2018;49:505-510.
Patel R, Alijanipour P, Parvizi J. Advancements in diagnosing periprosthetic joint infections after total hip and knee arthroplasty. Open Orthop J. 2016;10:654-661.
Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002;15:167-193.
Trampuz A, Widmer AF. Infections associated with orthopedic implants. Curr Opin Infect Dis. 2006;19:349-356.
Trampuz A, Zimmerli W. Diagnosis and treatment of infections associated with fracture-fixation devices. Injury. 2006;37(suppl 2):S59-S66.
Black DM, Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med. 2016;374:254-262.
Kovats S. Estrogen receptors regulate innate immune cells and signaling pathways. Cell Immunol. 2015;294:63-69.
Laffont S, Seillet C, Guery JC. Estrogen receptor-dependent regulation of dendritic cell development and function. Front Immunol. 2017;8:108.
Luo C, Wang L, Sun C, Li D. Estrogen enhances the functions of CD4(+)CD25(+)Foxp3(+) regulatory T cells that suppress osteoclast differentiation and bone resorption in vitro. Cell Mol Immunol. 2011;8:50-58.
Li H, Hong S, Qian J, Zheng Y, Yang J, Yi Q. Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells. Blood. 2010;116:210-217.
Morgenstern M, Erichsen C, von Rüden C, et al. Staphylococcal orthopaedic device-related infections in older patients. Injury. 2016;47:1427-1434.
Coxon FP, Thompson K, Rogers MJ. Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol. 2006;6:307-312.
McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354:821-831.
Eastell R, O'Neill TW, Hofbauer LC, et al. Postmenopausal osteoporosis. Nat Rev Dis Primers. 2016;2:16069.
Boyce BF, Xiu Y, Li J, Xing L, Yao Z. NF-κB-mediated regulation of osteoclastogenesis. Endocrinol Metab. 2015;30:35-44.
Reid IR, Cornish J. Epidemiology and pathogenesis of osteonecrosis of the jaw. Nat Rev Rheumatol. 2011;8:90-96.
Vermeer JA, Renders GA, Everts V. Osteonecrosis of the jaw-a bone site-specific effect of bisphosphonates. Curr Osteoporos Rep. 2016;14:219-225.
Elsayed R, Kurago Z, Cutler CW, et al. Role of dendritic cell-mediated immune response in oral homeostasis: a new mechanism of osteonecrosis of the jaw. FASEB J. 2020;34:2595-2608.
Feng X, Cai A. Assessing risks of impaired healing and osteomyelitis associated with bisphosphonates using FDA adverse event reporting system (FAERS). J Pharmacovigilance. 2015;3:158.
Stadelmann VA, Potapova I, Camenisch K, Nehrbass D, Richards RG, Moriarty TF. In vivo microCT monitoring of osteomyelitis in a rat model. BioMed Res Int. 2015;2015:587857.
Freitag L, Günther C, Eberli U, Fürst A, Zeiter S, Stadelmann VA. Relative effects of age on implant integration in a rat model: a longitudinal in vivo microct study. J Orthop Res. 2019;37:541-552.
Waarsing JH, Day JS, van der Linden JC, et al. Detecting and tracking local changes in the tibiae of individual rats: a novel method to analyse longitudinal in vivo micro-CT data. Bone. 2004;34:163-169.
Birkhold AI, Razi H, Weinkamer R, Duda GN, Checa S, Willie BM. Monitoring in vivo (re)modeling: a computational approach using 4D microCT data to quantify bone surface movements. Bone. 2015;75:210-221.
Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Müller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res. 2010;25:1468-1486.
Versalovic J, Koeuth T, Lupski JR. Distribution of repetitive DNA sequences in eubacteria and application to fingerprinting of bacterial genomes. Nucleic Acids Res. 1991;19:6823-6831.
Cenci S, Weitzmann MN, Roggia C, et al. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. The. J Clin Invest. 2000;106:1229-1237.
Roggia C, Gao Y, Cenci S, et al. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci U S A. 2001;98:13960-13965.
Jones RM, Mulle JG, Pacifici R. Osteomicrobiology: The influence of gut microbiota on bone in health and disease. Bone. 2018;115:59-67.
Rifas L, Arackal S, Weitzmann MN. Inflammatory T cells rapidly induce differentiation of human bone marrow stromal cells into mature osteoblasts. J Cell Biochem. 2003;88:650-659.
Tomkinson A, Gevers EF, Wit JM, Reeve J, Noble BS. The role of estrogen in the control of rat osteocyte apoptosis. J Bone Miner Res. 1998;13:1243-1250.
Tomkinson A, Reeve J, Shaw RW, Noble BS. The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. J Clin Endocrinol Metab. 1997;82:3128-3135.
Gilbert L, He X, Farmer P, et al. Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology. 2000;141:3956-3964.
Trampuz A, Zimmerli W. Antimicrobial agents in orthopaedic surgery: prophylaxis and treatment. Drugs. 2006;66:1089-1105.
Croes M, Boot W, Kruyt MC, et al. Inflammation-induced osteogenesis in a rabbit tibia model. Tissue engineering part C. Methods. 2017;23:673-685.
Croes M, Kruyt M, Boot W, et al. The role of bacterial stimuli in inflammation-driven bone formation. Eur Cell Mater. 2019;37:402-419.
Castleman MJ, Pokhrel S, Triplett KD, et al. Innate sex bias of Staphylococcus aureus skin infection is driven by alpha-hemolysin. J Immunol. 2018;200:657-668.
Dapunt U, Giese T, Stegmaier S, Moghaddam A, Hänsch GM. The osteoblast as an inflammatory cell: production of cytokines in response to bacteria and components of bacterial biofilms. BMC Musculoskelet Disord. 2016;17:243.
Marriott I, Gray DL, Rati DM, et al. Osteoblasts produce monocyte chemoattractant protein-1 in a murine model of Staphylococcus aureus osteomyelitis and infected human bone tissue. Bone. 2005;37:504-512.
Yang D, Wijenayaka AR, Solomon LB, et al. Novel insights into Staphylococcus aureus deep bone infections: the involvement of osteocytes. mBio. 2018. https://doi.org/10.1128/mBio.00415-18
Thillemann TM, Pedersen AB, Mehnert F, Johnsen SP, Søballe K. Postoperative use of bisphosphonates and risk of revision after primary total hip arthroplasty: a nationwide population-based study. Bone. 2010;46:946-951.
Li D, Gromov K, Proulx ST, et al. Effects of antiresorptive agents on osteomyelitis: novel insights into the pathogenesis of osteonecrosis of the jaw. Ann NY Acad Sci. 2010;1192:84-94.
Yamashita J, Sawa N, Sawa Y, Miyazono S. Effect of bisphosphonates on healing of tooth extraction wounds in infectious osteomyelitis of the jaw. Bone. 2020:115611.
Sing CW, Kiel DP, Hubbard RB, et al. 2020. Nitrogen-containing bisphosphonates are associated with reduced risk of pneumonia in patients with hip fracture. J Bone Miner Res. 2020;35:1676-1684.
Colón-Emeric CS, Mesenbrink P, Lyles KW, et al. Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res. 2010;25:91-97.
Bolland MJ, Grey AB, Gamble GD, Reid IR. Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab. 2010;95:1174-1181.
Center JR, Bliuc D, Nguyen ND, Nguyen TV, Eisman JA. Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endocrinol Metab. 2011;96:1006-1014.
Sambrook PN, Cameron ID, Chen JS, et al. Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study. Osteoporos Int. 2011;22:2551-2556.
Billington EO, Reid IR. Benefits of bisphosphonate therapy: beyond the skeleton. Curr Osteoporos Rep. 2020;18:587-596.
Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone. 2008;42:848-860.
Duckworth AD, McQueen MM, Tuck CE, et al. Effect of alendronic acid on fracture healing: a multicenter randomized placebo-controlled trial. J Bone Miner Res. 2019;34:1025-1032.
Lim SJ, Yeo I, Yoon PW, et al. Incidence, risk factors, and fracture healing of atypical femoral fractures: a multicenter case-control study. Osteoporos Int. 2018;29:2427-2435.
Allen MR. Skeletal accumulation of bisphosphonates: implications for osteoporosis treatment. Expert Opin Drug Metab Toxicol. 2008;4:1371-1378.
Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Porras AG. Clinical pharmacology of alendronate sodium. Osteoporos Int. 1993;3(suppl 3):S13-S16.
Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397:315-323.
Cummings SR, Martin JS, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756-765.